Administration of adjuvant oxaliplatin to patients with stage III colon cancer is affected by age and hospital

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors thank the registration team of the Eindhoven Cancer Registry for their dedicated data collection. Furthermore, we would like to thank all the contributing hospitals: Amphia Hospital, Breda; Catharina Hospital, Eindhoven; Elkerliek Hospital, Helmond and Deurne; Hospital Bernhoven, Uden; Jeroen Bosch Hospital, ‘s Hertogenbosch; Máxima Medical Centre, Eindhoven and Veldhoven; St. Anna Hospital, Geldrop; St. Elisabeth Hospital, Tilburg; TweeSteden Hospital, Tilburg and Waalwijk; VieCuri Hospital, Venlo and Venray; Instituut Verbeeten, Tilburg.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

This work was supported by The Netherlands Organisation for Health Research and Development [grant number 113102004]. The funding source had no involvement in the study design, the collection, analysis and interpretation of data; in writing of the manuscript; and in the decision to submit the manuscript for publication.